In this regard, Qiu and co-workers36 reported that both primary and acquired resistance of breast cancer cell lines to the anti-human epidermal growth factor receptor 2 (HER2) mAb trastuzumab are both increased by Cullin7 (CUL7), a scaffold protein for the CUL7 E3 ubiquitin ligase that is overexpressed in the trastuzumab-resistant cells. The gene discussed is ERBB2; the disease is breast carcinoma.